Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry-Reference-Cited by-同舟云学术

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

Published:2010-05-06 Issue:9 Volume:62 Page:2625-2632
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Gottenberg J.-E.,Ravaud P.,Bardin T.,Cacoub P.,Cantagrel A.,Combe B.,Dougados M.,Flipo R. M.,Godeau B.,Guillevin L.,Loët X. Le,Hachulla E.,Schaeverbeke T.,Sibilia J.,Baron G.,Mariette X.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.27555/fullpdf

Reference21 articles.

1. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis;Edwards;N Engl J Med,2004

2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006

3. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial;Emery;Arthritis Rheum,2006

4. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists;Askling;Ann Rheum Dis,2007

5. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register;Dixon;Arthritis Rheum,2006

Cited by 261 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions;Seminars in Arthritis and Rheumatism;2024-08

2. The Future of CAR T Therapeutics to Treat Autoimmune Disorders;Molecular Diagnosis & Therapy;2024-07-30

3. Rituximab Use and the Increased Risk of Reactivation of Latent Tuberculosis?;Journal of Advanced Lung Health;2024-03-29

4. Connective tissue disease-associated interstitial lung disease;Jornal Brasileiro de Pneumologia;2024-02-28

5. Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis;Drug Safety;2024-02-07